Showing 15 posts of 22 posts found.

China approves Astellas’ Xtandi in non-metastatic castration-resistant prostate cancer

November 6, 2020
Medical Communications, Sales and Marketing Astellas, China, NMPA, Xtandi

China’s drug regulator, the National Medical Products Administration (NMPA), has given the green light to Astellas to market Xtandi (enzalutamide …

FDA approves Pfizer and Astellas Pharma’s prostate cancer drug

December 17, 2019
Manufacturing and Production Astellas Pharma, Cancer, FDA, Pfizer, Xtandi, prostate cancer

The FDA has approved Pfizer and Astellas Pharma’s Xtandi (enzalutamide) to treat patients with a type of prostate cancer. The …

Astellas’ Xtandi “significantly improves” progression-free survival in advanced hormone-sensitive prostate cancer

February 18, 2019
Research and Development, Sales and Marketing Astellas, Cancer, Xtandi, pharma, prostate cancer

Japanese pharma firm Astellas has lifted the curtain on new data for its androgen receptor signalling inhibitor Xtandi (enzalutamide), when …

FDA expands Pfizer and Astellas’ Xtandi into castration-resistant prostate cancer

July 16, 2018
Sales and Marketing Astellas, Cancer, FDA, Pfizer, US, Xtandi, pharma, prostate cancer

Astellas and Pfizer have revealed that their androgen receptor inhibitor Xtandi (enzalutamide) has received approval from the FDA to expand …

Pfizer receives prostate cancer drug boost with trial results

September 15, 2017
Medical Communications, Research and Development Astellas, Pfizer, Xtandi, biotech, drugs, pharma, pharmaceutical

Pfizer, and its partner Astellas Pharma, received a major boost to its plans for prostate cancer treatment, Xtandi, by announcing …


MSD joins Medivation race, says reports

August 18, 2016
Manufacturing and Production, Research and Development, Sales and Marketing MSD, Medivation, Merck, Pfizer, Sanofi, Xtandi, takeover

MSD, known as Merck in the US and Canada, is said to have declared its interest in buying US oncology …


AstraZeneca mulling a $10-billion bid for Medivation – report

July 12, 2016
Manufacturing and Production, Sales and Marketing AstraZeneca, Celgene, Medivation, Pfizer, Xtandi, cancer drug, merger and acquisition

Anglo Swedish drug firm AstraZeneca (LSE: AZN) is considering a $10-billion takeover bid for Medivation (Nasdaq: MDVN), according to reports. …

US lawmakers demand price cut for Astellas, Medivation’s prostate cancer drug Xtandi

March 30, 2016
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Astellas, Japan, Medivation, US FDA, Xtandi, drug price

US lawmakers have asked the National Institutes of Health and the Department of Health and Human Services to ‘use its …

NICE publishes draft guidance on two prostate cancer treatments

December 11, 2015
Medical Communications, Research and Development, Sales and Marketing Astellas, Janssen, NICE, Xtandi, Zytiga, prostate cancer

NICE has issued final draft guidance recommending Astellas Pharma’s Xtandi (enzalutamide) in prostate cancer prior to chemotherapy, but not Janssen’s …


Astellas in ‘unacceptable’ Xtandi ABPI code breach

July 3, 2015
Medical Communications, Sales and Marketing ABPI Code, Astella, PMCPA, Xtandi

The industry code of conduct regulator has singled out Astellas for ‘particular censure’ for arranging a meeting for UK healthcare …

Celgene image

NICE rejects Otelza but SMC recommends it

June 11, 2015
Sales and Marketing Astellas, Celgene, NHS, NICE, SMC, Xtandi, otezla

Draft guidance issued by NICE has seen rejections for products including Celgene’s Otelza and Astellas Pharma’s Xtandi, and a call …

Afinitor image

Mixed bag for Novartis and Astellas in breast cancer

December 15, 2014
Research and Development, Sales and Marketing Afinitor, Astellas, Novartis, Xtandi, enzalutamide, everolimus

Preliminary results from a Phase II trial of Astellas’ Xtandi (enzalutamide) show positive benefits for the prostate cancer drug when …

FDA approves new indication for Xtandi

September 11, 2014
Sales and Marketing Astellas, FDA, Medivation, Xtandi, Zytiga, prostate

The FDA has approved Astellas Pharma and Medivation’s prostate cancer drug Xtandi (enzalutamide) for use in patients who have not …

Yervoy image

NICE ‘yes’ for cancer drugs

July 23, 2014
Sales and Marketing Astellas, BMS, Cancer, NICE, Xtandi, Yervoy

Two big-name oncology brands, Bristol-Myers Squibb’s Yervoy and Astellas Pharma’s Xtandi, have been given the nod by drug costs watchdog …

NICE recommends Xtandi

May 9, 2014
Sales and Marketing Astellas, NICE, Xtandi, abiraterone, prostate

NICE has reiterated that Astellas Pharma’s Xtandi should be used to treat NHS prostate cancer patients – but has removed …

Latest content